
Baricitinib Restores Hair Growth in Adolescents With AA
3 天之前 · Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.
Aggressive Ablation Better Than Regular for AF - Medscape
3 天之前 · Aggressive ablation shows better clinical outcomes than regular ablation in patients with persistent atrial fibrillation.
HIIT Reduces Risk for Kidney Function Decline in Seniors
2025年3月11日 · Long-term high-intensity interval training may reduce the risk for the decline of kidney function in older adults, a study reveals.
Do We Really Know the Stroke Risk From AF? - Medscape
2025年2月4日 · There is growing evidence that the risk for stroke in patients with untreated AF is declining, changing the risk-benefit calculus for anticoagulation.
Tezepelumab Eases Chronic Rhinosinusitis With Nasal Polyps
2025年3月10日 · The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a phase 3 trial.
Delgocitinib Cream Produces Robust Response to Eczema
2025年3月9日 · Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped treatment stayed clear or nearly clear for 8 weeks.
Early Surgery Cuts Healthcare Use in Pediatric Sleep Apnea
3 天之前 · Early adenotonsillectomy in children with mild sleep-disordered breathing reduces total healthcare encounters and prescription medications.
Low-Dose Minocycline Bests Doxycycline as Rosacea Rx
2025年3月7日 · Patients with moderate to severe papulopustular rosacea have better outcomes with low-dose minocycline than with placebo and doxycycline, according to two randomized trials.
Prostate Cancer Patient Develops Rare Penile Metastases
4 天之前 · A 68-year-old man with prostate cancer developed penile metastasis, a rare but serious complication, reinforcing the need for thorough examination and early detection.
FDA Okays Tenecteplase for Acute Ischemic Stroke - Medscape
2025年3月4日 · Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.